Efficacy, Safety, and Biomarkers of Single-Agent Bevacizumab Therapy in Patients with Advanced Hepatocellular CarcinomaValérie Boige, Françoise Farace|The Oncologist|2012Cited by 132
Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant modelVincent Faugeroux, Françoise Farace|Nature Communications|2020Cited by 80
Targeting genome integrity dysfunctions impedes metastatic potency in non–small cell lung cancer circulating tumor cell–derived explantsTala Tayoun, Françoise Farace|JCI Insight|2022Cited by 43
Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castrationresistant prostate cancer: a report from the PETRUS prospective studyChristophe Massard, Françoise Farace|Oncotarget|2016Cited by 36
Abstract LB-302: A comprehensive study of translational research and safety exploration of the vascular disrupting agent (VDA) AVE8062 in combination with cisplatin administered every 3 weeks to patients with advanced solid tumorsJean‐Charles Soria, Luca Gianni, Jean‐Pierre Armand et al.|Cancer Research|2008Cited by 8